Nacif v. Athira Pharma Inc

CourtDistrict Court, W.D. Washington
DecidedFebruary 17, 2023
Docket2:21-cv-00861
StatusUnknown

This text of Nacif v. Athira Pharma Inc (Nacif v. Athira Pharma Inc) is published on Counsel Stack Legal Research, covering District Court, W.D. Washington primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Nacif v. Athira Pharma Inc, (W.D. Wash. 2023).

Opinion

1 2 UNITED STATES DISTRICT COURT WESTERN DISTRICT OF WASHINGTON 3 AT SEATTLE 4 ANTONIO BACHAALANI NACIF 5 and WIES RAFI, individually and on behalf of all others similarly situated, 6 Plaintiffs, C21-0861 TSZ 7 v. ORDER 8 ATHIRA PHARMA, INC.; and LEEN 9 KAWAS, Ph.D., Defendants. 10

11 THIS MATTER comes before the Court on a motion, docket no. 105, brought by 12 Goldman Sachs & Co. LLC, Jeffries LLC, JMP Securities LLC, and Stifel Nicolaus & 13 Company, Inc. (collectively, “Underwriter Defendants”), seeking entry of a partial 14 judgment pursuant to Federal Rule of Civil Procedure 54(b). Having reviewed all papers 15 filed in support of, and in opposition to, the motion, the Court enters the following Order. 16 Background 17 By Order entered July 29, 2022, docket no. 89, the Court granted in part and 18 denied in part a motion to dismiss brought by defendants Athira Pharma, Inc. (“Athira”), 19 Leen Kawas, Ph.D., Athira’s Chief Financial Officer (“CFO”) Glenna Mileson, Athira’s 20 Board of Directors members Joseph Edelman, John M. Fluke, Jr., and James A. Johnson, 21 and the Underwriter Defendants. See Order (docket no. 89). Of plaintiffs’ five claims, 22 only three were asserted against the Underwriter Defendants, namely (a) plaintiffs’ first 1 claim under § 10(b) of the Securities Exchange Act of 1934 (“Exchange Act”) and 2 U.S. Securities and Exchange Commission Rule 10b-5, (b) plaintiffs’ third claim under

3 § 11 of the Securities Act of 1933 (“Securities Act”), and (c) plaintiffs’ fourth claim 4 under § 12 of the Securities Act. See Order at 28–29 (docket no. 89). 5 Plaintiffs’ first claim was dismissed without prejudice and with leave to amend as 6 to Athira and the individual defendants for failure to adequately plead scienter, but with 7 prejudice as to the Underwriter Defendants based on plaintiffs’ clarification that they do 8 not assert a § 10(b) / Rule 10b-5 claim against those four defendants. See id. at 29–32,

9 38–39, & 42–47. Plaintiffs’ third claim was dismissed without prejudice and with leave 10 to amend, except as to Athira and Dr. Kawas with respect to Statement 3. Id. at 36–42. 11 Plaintiffs’ fourth claim was dismissed with prejudice as to all defendants in light of 12 concessions made by named plaintiffs Antonio Bachaalani Nacif and Wies Rafi. Id. at 13 29. The following table summarizes the Court’s previous rulings, none of which bind

14 putative class members. 15 ↓ Defendant | Claim → § 10(b)/Rule 10b-5 § 11 § 12(a)(2) 16 dismissed without Athira Pharma, Inc. prejudice and with 17 dismissed without leave to amend as 18 Leen Kawas, Ph.D. prejudice and with to all statements dismissed with leave to amend except Statement 3 prejudice as to 19 CFO Glenna Mileson ( pf la ei al du r se c t io en a td ee r)q uately dismissed without N (cla ac imif wan itd hd R raa wf ni

20 Board of Directors prejudice and with by named plaintiffs) (Edelman, Fluke, & Johnson) leave to amend as 21 to all statements dismissed with Underwriter Defs. prejudice 22 1 In its earlier Order, the Court set a deadline of August 19, 2022, for plaintiffs to 2 file a second amended complaint. See id. at 50. Plaintiffs have not done so. The Court

3 later set a deadline of December 16, 2022, for joining additional parties. Minute Order 4 at 1 (docket no. 100). No parties have been joined or re-joined. The Underwriter 5 Defendants now ask the Court to enter final judgment in their favor. Defs.’ Mot. (docket 6 no. 105). Plaintiffs oppose the motion, arguing that the dismissal of their § 11 claim is 7 not “final” for purposes of Rule 54(b), and that the current situation does not warrant 8 entry of a partial judgment in favor of the Underwriter Defendants. Pls.’ Resp. (docket

9 no. 111). 10 Discussion 11 A. Applicable Standards 12 The Court may enter final judgment “as to one or more, but fewer than all, claims 13 or parties” if it “expressly determines” that “no just reason for delay” exists. Fed. R. Civ.

14 P. 54(b). A decision is “final” if it constitutes “an ultimate disposition of an individual 15 claim.” Curtiss-Wright Corp. v. Gen. Elec. Co., 446 U.S. 1, 7 (1980). Not all final 16 judgments on individual claims in a multiple-claim action should be immediately 17 appealable, and the Court’s role under Rule 54(b) is to serve as a “dispatcher.” Id. at 8. 18 In doing so, the Court must consider both “judicial administrative interests” and “the

19 equities involved.” See id. 20 The former (juridical) factors include whether the decided claims are “separable 21 from the others remaining to be adjudicated” and “whether the nature of the claims 22 already determined was such that no appellate court would have to decide the same issues 1 more than once even if there were subsequent appeals.” Id. They aim to preserve “the 2 historic federal policy against piecemeal appeals.” Id.; see also Wood v. GCC Bend,

3 LLC, 422 F.3d 873, 879–82 (9th Cir. 2005) (reversing a Rule 54(b) certification as to the 4 dismissal of constructive discharge claims, which left remaining for trial claims based on 5 an allegedly discriminatory demotion, observing that “[t]he greater the overlap [in facts] 6 the greater the chance that [the Ninth Circuit] will have to revisit the same facts―spun 7 only slightly differently―in a successive appeal”). 8 In evaluating the equities relating to the timing of an appeal, the Court must

9 engage in a “reasonable” assessment. Curtiss-Wright, 446 U.S. at 10–11. In Curtiss- 10 Wright, the Supreme Court concluded that the district court did not abuse its discretion in 11 considering the difference between the statutory and market rates of interest, as well as 12 the facts that the debts at issue were “liquidated and large” and that, “absent Rule 54(b) 13 certification, the debts would not be paid for ‘many months, if not years’ because the rest

14 of the litigation would be expected to continue for that period of time.” Id. at 11. The 15 Curtiss-Wright Court eschewed any requirement that economic duress or insolvency be 16 shown to qualify for a partial judgment under Rule 54(b), observing that both parties in 17 the matter were financially sound. Id. at 12. Thus, the district court had properly viewed 18 economic health as a neutral factor in weighing the equities, especially given that it could

19 and did stay execution on the Rule 54(b) judgment pending appeal. Id. at 12–13 & n.3. 20 B. Proper Scope of Rule 54(b) Certification 21 In asking for entry of a partial judgment in only their favor, the Underwriter 22 Defendants offered no basis for distinguishing between them and the other defendants. If 1 the Court were to certify solely the claims asserted against the Underwriter Defendants, it 2 would be serving up at least two appeals involving the same facts, one now involving the

3 Underwriter Defendants and another later concerning the other defendants. The Court 4 declines to enter partial judgment in a manner that might require the Ninth Circuit to 5 “decide the same issues on sequential appeals rather than once as a single unit.” See 6 Abdo v. Fitzsimmons, Nos. 17-cv-851 & 17-cv-1232, 2021 WL 3493169, at *3 (N.D. Cal. 7 May 17, 2021). 8 The procedural posture of this case, however, might support a broader Rule 54(b)

9 certification. With regard to the § 10(b) / Rule 10b-5 claim against the Underwriter 10 Defendants and the § 12 claim against all defendants, the dismissal was premised on 11 plaintiffs’ withdrawal of the claims, and no appeal is anticipated.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Nacif v. Athira Pharma Inc, Counsel Stack Legal Research, https://law.counselstack.com/opinion/nacif-v-athira-pharma-inc-wawd-2023.